vs
Side-by-side financial comparison of QuidelOrtho Corp (QDEL) and Bristow Group Inc. (VTOL). Click either name above to swap in a different company.
QuidelOrtho Corp is the larger business by last-quarter revenue ($699.9M vs $377.3M, roughly 1.9× Bristow Group Inc.). Bristow Group Inc. runs the higher net margin — 4.9% vs -104.7%, a 109.6% gap on every dollar of revenue. On growth, Bristow Group Inc. posted the faster year-over-year revenue change (6.7% vs -3.7%). Bristow Group Inc. produced more free cash flow last quarter ($47.8M vs $-94.7M). Over the past eight quarters, Bristow Group Inc.'s revenue compounded faster (5.8% CAGR vs -2.9%).
QuidelOrtho Corporation is an American manufacturer of diagnostic healthcare products that are sold worldwide.
Bristow Helicopters Limited is a British civil helicopter operator originally based at Aberdeen Airport, Scotland, which is currently a part of the U.S.-based Bristow Group which in turn has its corporate headquarters in Houston, Texas, U.S. In 2020, Bristow Group was merged with Era Helicopters, a large U.S.-based commercial helicopter operator that was previously a division of Era Aviation, with the two companies then continuing to use the Bristow name.
QDEL vs VTOL — Head-to-Head
Income Statement — Q3 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $699.9M | $377.3M |
| Net Profit | $-733.0M | $18.4M |
| Gross Margin | — | — |
| Operating Margin | -100.7% | 8.5% |
| Net Margin | -104.7% | 4.9% |
| Revenue YoY | -3.7% | 6.7% |
| Net Profit YoY | -3583.4% | -42.1% |
| EPS (diluted) | $-10.78 | $0.61 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $377.3M | ||
| Q3 25 | $699.9M | $386.3M | ||
| Q2 25 | $613.9M | $376.4M | ||
| Q1 25 | $692.8M | $350.5M | ||
| Q4 24 | $707.8M | $353.5M | ||
| Q3 24 | $727.1M | $365.1M | ||
| Q2 24 | $637.0M | $359.7M | ||
| Q1 24 | $711.0M | $337.1M |
| Q4 25 | — | $18.4M | ||
| Q3 25 | $-733.0M | $51.5M | ||
| Q2 25 | $-255.4M | $31.7M | ||
| Q1 25 | $-12.7M | $27.4M | ||
| Q4 24 | $-178.4M | $31.8M | ||
| Q3 24 | $-19.9M | $28.2M | ||
| Q2 24 | $-147.7M | $28.2M | ||
| Q1 24 | $-1.7B | $6.6M |
| Q4 25 | — | 8.5% | ||
| Q3 25 | -100.7% | 13.1% | ||
| Q2 25 | -29.4% | 11.3% | ||
| Q1 25 | 4.7% | 9.6% | ||
| Q4 24 | -14.2% | 9.0% | ||
| Q3 24 | 2.1% | 9.1% | ||
| Q2 24 | -18.4% | 12.4% | ||
| Q1 24 | -247.3% | 6.8% |
| Q4 25 | — | 4.9% | ||
| Q3 25 | -104.7% | 13.3% | ||
| Q2 25 | -41.6% | 8.4% | ||
| Q1 25 | -1.8% | 7.8% | ||
| Q4 24 | -25.2% | 9.0% | ||
| Q3 24 | -2.7% | 7.7% | ||
| Q2 24 | -23.2% | 7.8% | ||
| Q1 24 | -239.9% | 2.0% |
| Q4 25 | — | $0.61 | ||
| Q3 25 | $-10.78 | $1.72 | ||
| Q2 25 | $-3.77 | $1.07 | ||
| Q1 25 | $-0.19 | $0.92 | ||
| Q4 24 | $-2.54 | $1.07 | ||
| Q3 24 | $-0.30 | $0.95 | ||
| Q2 24 | $-2.20 | $0.96 | ||
| Q1 24 | $-25.50 | $0.23 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $98.1M | $286.2M |
| Total DebtLower is stronger | $2.5B | $671.5M |
| Stockholders' EquityBook value | $2.0B | $1.1B |
| Total Assets | $5.7B | $2.3B |
| Debt / EquityLower = less leverage | 1.23× | 0.63× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $286.2M | ||
| Q3 25 | $98.1M | $245.5M | ||
| Q2 25 | $151.7M | $251.8M | ||
| Q1 25 | $127.1M | $191.1M | ||
| Q4 24 | $98.3M | $247.5M | ||
| Q3 24 | $143.7M | $200.3M | ||
| Q2 24 | $107.0M | $178.6M | ||
| Q1 24 | $78.5M | $140.6M |
| Q4 25 | — | $671.5M | ||
| Q3 25 | $2.5B | $675.0M | ||
| Q2 25 | $2.1B | $705.2M | ||
| Q1 25 | $2.1B | $701.9M | ||
| Q4 24 | $2.1B | $689.8M | ||
| Q3 24 | $2.2B | $629.1M | ||
| Q2 24 | $2.2B | $594.2M | ||
| Q1 24 | $2.2B | $544.1M |
| Q4 25 | — | $1.1B | ||
| Q3 25 | $2.0B | $1.0B | ||
| Q2 25 | $2.8B | $984.4M | ||
| Q1 25 | $3.0B | $931.7M | ||
| Q4 24 | $3.0B | $891.7M | ||
| Q3 24 | $3.2B | $899.2M | ||
| Q2 24 | $3.2B | $849.1M | ||
| Q1 24 | $3.3B | $820.7M |
| Q4 25 | — | $2.3B | ||
| Q3 25 | $5.7B | $2.3B | ||
| Q2 25 | $6.4B | $2.3B | ||
| Q1 25 | $6.5B | $2.2B | ||
| Q4 24 | $6.4B | $2.1B | ||
| Q3 24 | $6.8B | $2.1B | ||
| Q2 24 | $6.7B | $2.0B | ||
| Q1 24 | $6.7B | $1.9B |
| Q4 25 | — | 0.63× | ||
| Q3 25 | 1.23× | 0.65× | ||
| Q2 25 | 0.74× | 0.72× | ||
| Q1 25 | 0.70× | 0.75× | ||
| Q4 24 | 0.72× | 0.77× | ||
| Q3 24 | 0.68× | 0.70× | ||
| Q2 24 | 0.70× | 0.70× | ||
| Q1 24 | 0.68× | 0.66× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-45.5M | $76.9M |
| Free Cash FlowOCF − Capex | $-94.7M | $47.8M |
| FCF MarginFCF / Revenue | -13.5% | 12.7% |
| Capex IntensityCapex / Revenue | 7.0% | 7.7% |
| Cash ConversionOCF / Net Profit | — | 4.17× |
| TTM Free Cash FlowTrailing 4 quarters | $-153.1M | $56.4M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $76.9M | ||
| Q3 25 | $-45.5M | $23.1M | ||
| Q2 25 | $-46.8M | $99.0M | ||
| Q1 25 | $65.6M | $-603.0K | ||
| Q4 24 | $63.7M | $51.1M | ||
| Q3 24 | $117.9M | $66.0M | ||
| Q2 24 | $-97.9M | $33.7M | ||
| Q1 24 | $-700.0K | $26.7M |
| Q4 25 | — | $47.8M | ||
| Q3 25 | $-94.7M | $-6.2M | ||
| Q2 25 | $-84.3M | $67.4M | ||
| Q1 25 | $9.4M | $-52.7M | ||
| Q4 24 | $16.5M | $-32.4M | ||
| Q3 24 | $71.4M | $9.0M | ||
| Q2 24 | $-133.2M | $-16.7M | ||
| Q1 24 | $-66.8M | $-37.9M |
| Q4 25 | — | 12.7% | ||
| Q3 25 | -13.5% | -1.6% | ||
| Q2 25 | -13.7% | 17.9% | ||
| Q1 25 | 1.4% | -15.0% | ||
| Q4 24 | 2.3% | -9.2% | ||
| Q3 24 | 9.8% | 2.5% | ||
| Q2 24 | -20.9% | -4.6% | ||
| Q1 24 | -9.4% | -11.2% |
| Q4 25 | — | 7.7% | ||
| Q3 25 | 7.0% | 7.6% | ||
| Q2 25 | 6.1% | 8.4% | ||
| Q1 25 | 8.1% | 14.9% | ||
| Q4 24 | 6.7% | 23.6% | ||
| Q3 24 | 6.4% | 15.6% | ||
| Q2 24 | 5.5% | 14.0% | ||
| Q1 24 | 9.3% | 19.2% |
| Q4 25 | — | 4.17× | ||
| Q3 25 | — | 0.45× | ||
| Q2 25 | — | 3.12× | ||
| Q1 25 | — | -0.02× | ||
| Q4 24 | — | 1.61× | ||
| Q3 24 | — | 2.34× | ||
| Q2 24 | — | 1.20× | ||
| Q1 24 | — | 4.04× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
QDEL
| Labs | $373.8M | 53% |
| Point Of Care | $164.6M | 24% |
| Immunohematology | $142.0M | 20% |
| Donor Screening | $14.7M | 2% |
| Molecular Diagnostics | $4.8M | 1% |
| Collaborative Arrangement Transaction With Party To Collaborative Arrangement | $2.1M | 0% |
VTOL
| Offshore Energy Services | $247.5M | 66% |
| Government Services | $100.1M | 27% |
| Other | $21.9M | 6% |
| Related Party | $7.8M | 2% |
